Unlearn.AI

Unlearn.AI is developing a digital twin platform to conduct faster and smaller clinical trials on patients. The technological platform, TwinRCT, uses ML and historical data to conduct randomized trials by altering the digital twin to obtain primary and secondary outcomes of treatment effects. The historical data gathered is incorporated into the digital twin to gather demographic information, test results, and biomarkers to replicate actual patient records in the clinical trial. 

The platform covers various disease areas, including Alzheimer’s, multiple sclerosis, Parkinson’s, and ulcerative colitis. Furthermore, this platform is approved by the European Medicines Agency as a methodology for Phase II and III clinical studies. It is also approved by the FDA for state-side clinical trials.

Key customers and partnerships

The company operates a B2B business model and provides services to pharma sponsors, biotechnological companies, and academic institutions.

In February 2022, the company entered a multi-year collaboration with German pharma company Merck KGaA to incorporate the TwinRCT in randomized controlled trials in its immunology products. Further in June 2023, it partnered with QurAlis for ALS therapy trials and in September 2024, it partnered with ProJenX to enhance ProJenX's Phase I clinical trial of prosetin, a MAP4 kinase inhibitor, for ALS treatment.

In December 2024, it partnered with APST Research to integrate data from over 8,000 ALS patients into Unlearn's Digital Twin Generator (DTG).